Unknown

Dataset Information

0

First-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients.


ABSTRACT: This study evaluated the safety and feasibility of transendocardial injections of VentriGel, a cardiac extracellular matrix hydrogel, in early and late post-myocardial infarction (MI) patients with left ventricular (LV) dysfunction. VentriGel was delivered in 15 patients with moderate LV dysfunction (25% ≤ LV ejection fraction ≤ 45%) who were between 60 days to 3 years post-MI and were revascularized by percutaneous coronary intervention. The primary endpoints were incidence of adverse events and abnormal clinical laboratory results. This first-in-man study established the safety and feasibility of delivering VentriGel in post-MI patients, thus warranting further evaluation in larger, randomized clinical trials.

SUBMITTER: Traverse JH 

PROVIDER: S-EPMC6834965 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3848875 | biostudies-literature
| S-EPMC7855456 | biostudies-literature
| S-EPMC6277008 | biostudies-literature
| S-EPMC6383988 | biostudies-literature
| S-EPMC3349831 | biostudies-other
| S-EPMC5319826 | biostudies-literature
| S-EPMC8093531 | biostudies-literature
| S-EPMC6237773 | biostudies-literature
| S-EPMC8282997 | biostudies-literature
| S-EPMC4605352 | biostudies-literature